Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare,…
Pharma and The Fortune 500: Where Do Companies Rank?
Fortune released its annual list of the Fortune 500 companies, which rank the companies in the US with the largest revenues. So how did pharmaceutical companies and suppliers score in…
A recent study by PwC examines the thinking and strategic direction of CEOs and how their views compare with the perceptions and expectations of investment professionals. So what did the…
Supplier Risks and Cybersecurity: What Should Be on Your Radar?
The US Securities and Exchange Commission (SEC) has issued an interpretive release to provide guidance to public companies when preparing disclosures about cybersecurity risks and incidents. The release also communicates…
The Opportunities and Challenges for Novartis’ New CEO
Vasant Narasimhan, MD, took the helm of Novartis on February 1, 2018, assuming the role of CEO following the retirement of former CEO Joseph Jimenez. So what does the new…
Which executives and other leaders may have the largest impact for the pharmaceutical industry in 2018? DCAT Value Chain Insights offers a top ten ranking. Which executives should be on…
From CEOs: Optimism Prevails on Global Growth Prospects
So what is on the minds of CEOs? PwC’s annual study released this week at the World Economic Forum in Davos, Switzerland shows a record-breaking level of optimism among CEOs…
Pharma Companies Raise Supply Concerns Post Brexit
As the UK seeks to exit the European Union (EU), the pharmaceutical industry has raised concerns over the impact of Brexit. A recent study by the European Federation of Pharmaceutical…
Pfizer announced earlier this month that it is considering strategic alternatives to its consumer healthcare business. So what options may be ahead? The over-the-counter (OTC) drug market has seen several…
A Changing of the Guard at Novartis: What Is In Store?
Earlier this month, Novartis announced that Joseph Jimenez, current CEO , will step down as CEO in February 2018 and turn the reins over to Vasant Narasimhan, MD, current global…
